Verona Pharma Price To Sales vs. Shares Owned By Institutions
VRNA Stock | USD 41.42 2.16 5.50% |
Verona Pharma Price To Sales Ratio |
|
For Verona Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Verona Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Verona Pharma PLC utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Verona Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Verona Pharma PLC over time as well as its relative position and ranking within its peers.
Verona |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.00) | Revenue Per Share 0.07 | Return On Assets (0.28) | Return On Equity (0.78) |
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Verona Pharma PLC Shares Owned By Institutions vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Verona Pharma's current stock value. Our valuation model uses many indicators to compare Verona Pharma value to that of its competitors to determine the firm's financial worth. Verona Pharma PLC is rated third in price to sales category among its peers. It is rated below average in shares owned by institutions category among its peers producing about 0.15 of Shares Owned By Institutions per Price To Sales. The ratio of Price To Sales to Shares Owned By Institutions for Verona Pharma PLC is roughly 6.53 . At present, Verona Pharma's Price To Sales Ratio is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Verona Pharma's earnings, one of the primary drivers of an investment's value.Verona Shares Owned By Institutions vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Verona Pharma |
| = | 581.43 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Verona Pharma |
| = | 88.99 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Verona Shares Owned By Institutions Comparison
Verona Pharma is currently under evaluation in shares owned by institutions category among its peers.
Verona Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Verona Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Verona Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Verona Pharma's change in net profit over the period of time. It can combine multiple indicators of Verona Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last Reported | Projected for Next Year | ||
Accumulated Other Comprehensive Income | -4.1 M | -3.9 M | |
Operating Income | -67.8 M | -64.4 M | |
Income Before Tax | -55.2 M | -52.5 M | |
Total Other Income Expense Net | 12.6 M | 13.2 M | |
Net Loss | -54.6 M | -51.9 M | |
Income Tax Expense | -632.4 K | -664.1 K | |
Net Loss | -50.7 M | -48.2 M | |
Net Loss | -61.8 M | -58.7 M | |
Interest Income | 11.3 M | 11.9 M | |
Net Interest Income | 9.7 M | 10.2 M | |
Change To Netincome | 21.7 M | 22.8 M | |
Net Loss | (0.69) | (0.72) | |
Income Quality | 0.92 | 0.62 | |
Net Income Per E B T | 0.98 | 0.73 |
Verona Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Verona Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Verona Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Verona Pharma's important profitability drivers and their relationship over time.
Use Verona Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Verona Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Verona Pharma will appreciate offsetting losses from the drop in the long position's value.Verona Pharma Pair Trading
Verona Pharma PLC Pair Trading Analysis
The ability to find closely correlated positions to Verona Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Verona Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Verona Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Verona Pharma PLC to buy it.
The correlation of Verona Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Verona Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Verona Pharma PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Verona Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Verona Pharma position
In addition to having Verona Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Emerging Markets ETFs Thematic Idea Now
Emerging Markets ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Emerging Markets ETFs theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Emerging Markets ETFs Theme or any other thematic opportunities.
View All Next | Launch |
Check out World Market Map. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
To fully project Verona Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Verona Pharma PLC at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Verona Pharma's income statement, its balance sheet, and the statement of cash flows.